RS49521B - (1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat - Google Patents

(1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat

Info

Publication number
RS49521B
RS49521B YU46196A YU46196A RS49521B RS 49521 B RS49521 B RS 49521B YU 46196 A YU46196 A YU 46196A YU 46196 A YU46196 A YU 46196A RS 49521 B RS49521 B RS 49521B
Authority
RS
Serbia
Prior art keywords
phenylpiperidin
hydroxyphenyl
hydroxy
propanol methanesulfonate
methanesulfonate trihydrate
Prior art date
Application number
YU46196A
Other languages
English (en)
Inventor
Marta Maria Andino
Gene Sinay Terry
Eugene Fred Fiese
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU46196A publication Critical patent/YU46196A/sh
Publication of RS49521B publication Critical patent/RS49521B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

(1S, 2S)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat. Prijava sadrži još 1 nezavisan patentni zahtev.
YU46196A 1995-08-11 1996-08-09 (1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat RS49521B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (2)

Publication Number Publication Date
YU46196A YU46196A (sh) 1999-07-28
RS49521B true RS49521B (sr) 2006-10-27

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
YU46196A RS49521B (sr) 1995-08-11 1996-08-09 (1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat

Country Status (41)

Country Link
US (1) US6008233A (sr)
EP (1) EP0843661B1 (sr)
JP (1) JP3099072B2 (sr)
KR (1) KR100291882B1 (sr)
CN (2) CN1198739A (sr)
AP (1) AP755A (sr)
AR (1) AR004676A1 (sr)
AT (1) ATE215072T1 (sr)
AU (1) AU710984B2 (sr)
BG (1) BG63678B1 (sr)
BR (1) BR9610766A (sr)
CA (1) CA2228752C (sr)
CO (1) CO4750830A1 (sr)
CZ (1) CZ296236B6 (sr)
DE (1) DE69620191T2 (sr)
DK (1) DK0843661T3 (sr)
DZ (1) DZ2083A1 (sr)
ES (1) ES2170857T3 (sr)
GT (1) GT199600051A (sr)
HR (1) HRP960372B1 (sr)
HU (1) HUP9802862A3 (sr)
IL (1) IL122649A (sr)
IS (1) IS1945B (sr)
MA (1) MA23957A1 (sr)
NO (1) NO310458B1 (sr)
NZ (1) NZ309134A (sr)
OA (1) OA10664A (sr)
PE (1) PE4898A1 (sr)
PL (1) PL185603B1 (sr)
PT (1) PT843661E (sr)
RO (1) RO120134B1 (sr)
RS (1) RS49521B (sr)
RU (1) RU2140910C1 (sr)
SA (1) SA96170171B1 (sr)
SK (1) SK284209B6 (sr)
TN (1) TNSN96104A1 (sr)
TR (1) TR199800208T1 (sr)
TW (1) TW495502B (sr)
UA (1) UA59341C2 (sr)
WO (1) WO1997007098A1 (sr)
ZA (1) ZA966760B (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046213A (en) * 1994-08-18 2000-04-04 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
RO120134B1 (ro) * 1995-08-11 2005-09-30 Pfizer Inc. Trihidrat de metansulfonat de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol şi compoziţie farmaceutică
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
CA2369695A1 (en) * 1999-04-09 2000-10-19 Manabu Itoh Agent for treating neuropathic pain
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
EP1363634A2 (en) * 2000-08-16 2003-11-26 PHARMACIA & UPJOHN COMPANY Compounds for the treatment of addictive disorders
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
IL161308A0 (en) 2001-10-19 2004-09-27 Toyama Chemical Co Ltd Alkyl ether derivatives or their salts
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
CN102834384A (zh) 2009-12-11 2012-12-19 盐野义制药株式会社 *嗪衍生物
WO2012057248A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 ナフチリジン誘導体
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
RU2017107558A (ru) 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
EP3197440A4 (en) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US6046213A (en) * 1994-08-18 2000-04-04 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
RO120134B1 (ro) * 1995-08-11 2005-09-30 Pfizer Inc. Trihidrat de metansulfonat de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol şi compoziţie farmaceutică

Also Published As

Publication number Publication date
IS4643A (is) 1997-12-30
HRP960372B1 (en) 2003-04-30
AR004676A1 (es) 1999-03-10
WO1997007098A1 (en) 1997-02-27
HUP9802862A3 (en) 1999-05-28
CA2228752C (en) 2002-12-10
TR199800208T1 (sr) 1998-05-21
ES2170857T3 (es) 2002-08-16
CZ296236B6 (cs) 2006-02-15
AU710984B2 (en) 1999-10-07
TW495502B (en) 2002-07-21
SK16698A3 (en) 1999-06-11
NO980574L (no) 1998-02-10
HRP960372A2 (en) 1998-04-30
US6008233A (en) 1999-12-28
IL122649A0 (en) 1998-08-16
HUP9802862A2 (hu) 1999-04-28
ZA966760B (en) 1998-02-09
EP0843661B1 (en) 2002-03-27
NO980574D0 (no) 1998-02-10
PT843661E (pt) 2002-07-31
TNSN96104A1 (fr) 2005-03-15
AP9600856A0 (en) 1996-10-31
ATE215072T1 (de) 2002-04-15
BR9610766A (pt) 1999-07-13
MX9801149A (es) 1998-05-31
UA59341C2 (uk) 2003-09-15
AU5908496A (en) 1997-03-12
MA23957A1 (fr) 1997-04-01
PL185603B1 (pl) 2003-06-30
SA96170171B1 (ar) 2006-05-20
PL325050A1 (en) 1998-07-06
BG102289A (en) 1998-09-30
CN1198739A (zh) 1998-11-11
CZ39098A3 (cs) 1999-02-17
IL122649A (en) 2001-08-26
PE4898A1 (es) 1998-03-16
CA2228752A1 (en) 1997-02-27
DZ2083A1 (fr) 2002-10-23
KR19990036321A (ko) 1999-05-25
CN1615861A (zh) 2005-05-18
OA10664A (en) 2000-11-06
SK284209B6 (en) 2004-11-03
JPH10510552A (ja) 1998-10-13
EP0843661A1 (en) 1998-05-27
NZ309134A (en) 1999-09-29
GT199600051A (es) 1997-12-26
DE69620191T2 (de) 2002-07-18
JP3099072B2 (ja) 2000-10-16
IS1945B (is) 2004-08-13
BG63678B1 (bg) 2002-09-30
YU46196A (sh) 1999-07-28
CO4750830A1 (es) 1999-03-31
RU2140910C1 (ru) 1999-11-10
RO120134B1 (ro) 2005-09-30
DK0843661T3 (da) 2002-07-22
AP755A (en) 1999-08-02
DE69620191D1 (de) 2002-05-02
KR100291882B1 (ko) 2001-10-26
NO310458B1 (no) 2001-07-09

Similar Documents

Publication Publication Date Title
RS49521B (sr) (1s, 2s)-1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol metansulfonat trihidrat
TR970073A2 (tr) Alfa adrenerjik resentör antagonistleri olarak pirimidindion pirimidintrion,triazindion, tetrahidrokinazolindion türevleri.
SV1996000005A (es) Quinazolinonas bisustituidas en 2,8
TR199600849A2 (tr) 1alfa-26 dihidroksi -D-homo-vitamin D3.
TR199600358A2 (tr) -Adrenerjik agonistleri.
MA23778A1 (fr) Purine-6-ones-2,9 disubstituees
TR27961A (tr) Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
KR960705925A (ko) Hu-B1.219, 신규한 사람 조혈 수용체(Hu-B1.219, A NOVEL HUMAN HEMA-TOPOIETIN RECEPTOR)
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE69618634D1 (de) 1,4-benzodioxin-derivate
DE69906149D1 (de) 4,5-azolo-oxindole
FR2718478B1 (fr) Plinthe démontable.
IT1297636B1 (it) Macchina per la lavorazione di legno.
TR199600889A2 (tr) Fungisit bilesikler (B).
DE69434974D1 (de) alpha-2,8 SIALYLTRANSFERASE
SI0843661T1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
ITSV960031A0 (it) Macchina spargipolvere.
IT235626Y1 (it) Macchina per i trattamenti di biotermolisi.
ITPD950052V0 (it) Dispositivo aspirante, particolarmente per w.c.
IT1274839B (it) Apparecchiatura perfezionata per trattamenti di dialisi.
IT1280417B1 (it) Composti a struttura 3,4 diidro-2-iodometil-2,5,7,8-tetrametil-2h-1 benzopiranica.
BR9610047A (pt) 1,3,4-oxadiazolin-2-onas
ES1032310Y (es) Puf zapatero.
ITBO940083V0 (it) Macchina per vibromassaggi.
ES1034067Y (es) Herramienta impregnadora.